In a 70-year-old patient with transthyretin cardiac amyloidosis on dabigatran who presents with atrial fibrillation, a ventricular rate of approximately 95 bpm, normal QRS duration, and markedly prolonged corrected QT interval (Bazett ≈524 ms, Fridericia ≈485 ms), what is the appropriate management?

Management of Atrial Fibrillation with Prolonged QTc in ATTR Cardiac Amyloidosis

Continue dabigatran anticoagulation without interruption, pursue aggressive rate control with digoxin (avoiding beta-blockers and calcium channel blockers due to restrictive physiology), and strongly consider early rhythm control with direct-current cardioversion or catheter ablation given the patient's relatively early disease stage. 1, 2, 3

Anticoagulation Management

Maintain full anticoagulation with dabigatran regardless of CHA2DS2-VA score. The 2024 ESC guidelines provide a Class I, Level B recommendation that oral anticoagulation is mandatory in all patients with AF and cardiac amyloidosis, independent of stroke risk scores 1. This reflects the unique thrombogenic substrate created by amyloid infiltration that confers stroke risk beyond traditional risk factors 4.

Dabigatran Dosing Considerations

• Current dose of 150 mg twice daily is appropriate if CrCl >30 mL/min 5
• Assess renal function immediately—the patient's age (70 years) and cardiac amyloidosis increase risk of renal impairment
• If CrCl 15-30 mL/min, reduce to 75 mg twice daily 5
• Avoid P-gp inhibitors (dronedarone, systemic ketoconazole) if CrCl <50 mL/min 5
• Do not discontinue anticoagulation for cardioversion—dabigatran provides adequate periprocedural anticoagulation

Rate vs. Rhythm Control Strategy

Prioritize rhythm control over rate control in this patient. The evidence strongly favors early rhythm control in ATTR-CA, particularly before advanced disease stages develop 3, 6.

Why Rhythm Control is Superior Here

• Rhythm control is substantially more effective when performed earlier in disease course 3
• In Stage I-II ATTR-CA, 64% of patients remain arrhythmia-free after ablation vs. only 10% in Stage III disease 6
• Maintenance of normal sinus rhythm is independently associated with improved survival in ATTR-CA 3
• AF ablation reduces hospitalizations for heart failure/arrhythmia (1.7 vs. 4 hospitalizations, p=0.005) 6
• Ablation associated with 62% mortality reduction (HR 0.38,95% CI 0.17-0.86) 6

Rate Control Challenges in ATTR-CA

Rate control is problematic in cardiac amyloidosis due to:

• Restrictive physiology makes beta-blockers and calcium channel blockers poorly tolerated 4, 7
• Autonomic dysfunction limits conventional rate control efficacy 4
• Conduction disease (already evident with QRS 104 ms) increases risk of complete heart block with AV nodal agents 2, 8

If rate control is necessary as bridge to rhythm control:

• Use digoxin as first-line agent—better tolerated in restrictive cardiomyopathy
• Target ventricular rate 80-100 bpm (lenient control)
• Avoid beta-blockers unless absolutely necessary; if required, use lowest effective dose with close monitoring

Rhythm Control Implementation

Immediate Actions

1. Direct-current cardioversion is appropriate first-line therapy 3

   • 45% of ATTR-CA patients with AF undergo cardioversion 3
   • Continue dabigatran throughout (no interruption needed if therapeutic >3 weeks)
   • Expect recurrence without additional therapy

2. Antiarrhythmic drug therapy should be initiated 3

   • Used in 35% of ATTR-CA patients with AF 3
   • Amiodarone is preferred given QTc prolongation already present
   • Avoid Class Ic agents (flecainide, propafenone) due to conduction disease
   • Sotalol is contraindicated with QTcB 524 ms (already >500 ms)

Definitive Rhythm Control

Strongly recommend catheter ablation consultation 6, 4, 7

• Most effective when performed in earlier disease stages (this patient appears Stage I-II based on ventricular rate tolerance and ambulatory status)
• Pulmonary vein isolation with additional substrate modification typically required 7
• 42% overall arrhythmia-free survival, but 64% in Stage I-II disease 6
• Associated with improved survival and reduced hospitalizations 6

Critical QTc Management

The markedly prolonged QTc (Bazett 524 ms, Fridericia 485 ms) requires immediate attention 9.

QTc Prolongation Significance

• QTc prolongation is a unique feature of ATTR-CA not seen in other cardiomyopathies 9
• Correlates with disease severity (NYHA class, NAC stage, NT-proBNP, troponin) 9
• Increases risk of torsades de pointes, particularly with QTc >500 ms

QTc-Specific Interventions

• Discontinue all QT-prolonging medications immediately
• Correct electrolytes: maintain K+ >4.5 mEq/L, Mg2+ >2.0 mg/dL
• Avoid sotalol, dofetilide, ibutilide for rhythm control
• If amiodarone used, monitor QTc closely (amiodarone less torsadogenic despite QT prolongation)
• Consider temporary pacing if symptomatic bradycardia limits rate control options

Common Pitfalls to Avoid

1. Do not reduce anticoagulation intensity based on bleeding concerns—stroke risk is extremely high 1, 2
2. Do not aggressively rate control with beta-blockers—worsens restrictive physiology 4
3. Do not delay rhythm control—efficacy decreases dramatically with disease progression 3, 6
4. Do not use rate control as definitive strategy—associated with worse outcomes than rhythm control 3
5. Do not overlook disease-modifying therapy—ensure patient evaluated for tafamidis, which improves survival and may reduce AF burden 3, 8

Monitoring Plan

• Continuous telemetry until rhythm/rate controlled
• Daily ECG to monitor QTc and rhythm
• Renal function assessment before any dose adjustments
• Electrolytes twice daily until stable
• Consider implantable loop recorder or device upgrade if recurrent arrhythmias despite therapy 8